BSE filing, NSE: DRREDDY. Summary written from the filing by ALFA Finder's alert engine.
Dr. Reddy's Laboratories Ltd: key numbers
- Share price
- ₹1,352.00
- Market cap
- ₹1,12,848 Cr
- Revenue (annual)
- ₹33,700 Cr
- Net profit (annual)
- ₹4,196 Cr
- P/E (TTM)
- 40.3×Sector 45.9×
- Promoter holding
- 26.63%-0.01% QoQ
- FII holding
- 20.30%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Dr. Reddy's Laboratories Ltd
All →Dr. Reddy's Laboratories Business Update
Dr Reddy's says USFDA closed its PAI and GMP inspection at Srikakulam FTO-SEZ Process Unit-02 with VAI classification. The outcome is closed with no monetary penalty.
Dr. Reddy's Laboratories Earnings Call Transcript: Key Takeaways
Revenue declined 1.5% YoY as lower Revlimid sales in North America offset strong double-digit growth in base business and emerging markets.
- Call
- Guides 25% growth
Dr. Reddy's Laboratories Management Change
Dr Reddy's appointed Akhil Ravi as Head API and Services and Senior Management Personnel, effective 13 November 2026. Ravi is the son-in-law of co-chairman G V Prasad.
Dr. Reddy's Laboratories Investor Presentation: Key Takeaways
Q2FY27 revenue ₹8,671 Cr (-1.5% YoY), EBITDA ₹1,783 Cr (20.6%), PAT ₹925 Cr (-36% YoY). Management stresses double-digit base-business growth excluding lenalidomide in North America.
Dr. Reddy's Laboratories Q2 FY27 Results: Net Profit ₹913.2 Cr, Down 31.7% YoY
Dr. Reddy's Laboratories Ltd reported revenue from operations of ₹8,698 Cr (-1.5% YoY) and net profit of ₹913.2 Cr (-31.7% YoY) for Q2 FY27.
- Key figure
- Net profit ₹913.2 Cr · -31.7% YoY
Dr. Reddy's Laboratories Other Announcement
Dr. Reddy's Laboratories Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, including notes on significant beneficial ownership.
Other adverse business impact announcements
All →Oriental Rail Infrastructure Adverse Business Impact
Oriental Rail's subsidiary Oriental Foundry had a fire at its Kutch plant on 28 October 2026. Damage is minimal, operations are unaffected and the loss is insured.
Capillary Technologies India Adverse Business Impact
Capillary Technologies received KPMG's final forensic report on a cyber-enabled payment fraud at a step-down subsidiary. Four disputed payments totalled EUR 3.04 million, about Rs.32.24 Crore.
- Value
- ₹32.24 Cr
Windlas Biotech Adverse Business Impact
Windlas Biotech disclosed a cyber security incident on 30 October 2026. It states no material impact on core operations, finances or business continuity.
Neogen Chemicals Adverse Business Impact
Neogen Chemicals reports continued fire disruption at MPP3; replacement plant partly built with trial runs underway. Recognized damage totals ₹348.16 crore; production shifted to other sites.
- Value
- ₹348.2 Cr
Hindustan Organic Chemicals Adverse Business Impact
Hindustan Organic Chemicals temporarily shuts down its Kochi Hydrogen plant from 29 October 2026 for pipeline repair and urgent maintenance. Reopening date to be communicated separately.
IIFL Capital Services Adverse Business Impact
IIFL Capital Services' subsidiary surrendered its SEBI Investment Adviser registration, effective October 28, 2026. The company states there is no material monetary impact and no penalty.